SAKAR HEALTHCARE LIMITED
Latest filings
- Trading window closed from Oct 1 until Q2 FY27 results · Compliance
- Sakar Healthcare appoints Secretarial Auditor for 5-year term · Management Changes
- All 4 resolutions passed at 22nd AGM; voting results declared · Board & Shareholder Meetings
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures and supplies pharmaceutical products, with oncology formulations as the growth focus and a domestic contract development and manufacturing (CDMO) business in the rest of the portfolio. Oncology contributed 38% of FY26 revenue of ₹251.736 crore, built around tech-transfer partnerships, dossier filings and marketing authorisations with global pharma names such as Accord-Intas, Torrent, Emcure, Glenmark and Zydus. The remaining business is a domestic CDMO service that earned about ₹35 crore in FY26, supplying formulations to Indian pharma companies. The biggest cost line is materials at 52.7% of revenue, followed by employee cost at 15.4% and depreciation at 9.4%. Production runs primarily from a EU GMP-certified Bavla facility, which currently sits at about 29% capacity utilisation. Q1 FY27 revenue of ₹72.97 crore was up 38% year-on-year, driven by new oncology market authorisations and export demand.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
SAKAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from SAKAR HEALTHCARE LIMITED's filed financials and exchange disclosures
What does SAKAR HEALTHCARE LIMITED do?
SAKAR HEALTHCARE LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE, trading under the symbol SAKAR.
Is SAKAR HEALTHCARE LIMITED profitable?
Yes. Over the trailing twelve months SAKAR HEALTHCARE LIMITED reported a net profit of ₹36 Cr on revenue of ₹272 Cr.
Does SAKAR HEALTHCARE LIMITED pay a dividend?
Not in the latest reported year — SAKAR HEALTHCARE LIMITED's dividend payout for FY26 was nil.
Is SAKAR HEALTHCARE LIMITED debt-free?
No. It reported borrowings of ₹55 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹55 Cr after cash. Debt stands at 0.17× equity. That is higher than 52% of its 166 Pharmaceuticals peers.
Is SAKAR HEALTHCARE LIMITED expensive compared with its peers?
On trailing P/E, SAKAR HEALTHCARE LIMITED ranks 129 of 158 in Pharmaceuticals — cheaper than 19% of them, against an industry median of 32.0×. This is a position, not a valuation judgement.
How much does the SAKAR HEALTHCARE LIMITED share price move in a day?
On a typical session SAKAR HEALTHCARE LIMITED moves 2.02% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
Where can I track SAKAR HEALTHCARE LIMITED's announcements?
Every NSE and BSE filing by SAKAR HEALTHCARE LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.